IPHA

NASDAQ open

Innate Pharma

0.91 USD
▼-0.03-3.13%
盘后 1.44 0.00%
2026-11-20
市值
$85.43M
市盈率
—
EPS
-0.56
股息率
—
52 周区间
0.88 – 2.71
成交量
11.87K
Beta
1.22
目标价
5.67
52W 低 0.8852W 高 2.71
价格走势

公司简介

Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company’s products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4; and Monalizumab, a dual checkpoint inhibitor that targets T Cells and NK Cells. It also develops IPH5201, a blocking ant...